ResMed Inc. (NYSE:RMD)’s share price reached a new 52-week high on Wednesday . The stock traded as high as $66.47 and last traded at $66.01, with a volume of 147,218 shares trading hands. The stock had previously closed at $65.51.

RMD has been the subject of several research analyst reports. Zacks Investment Research raised shares of ResMed from a “hold” rating to a “buy” rating and set a $65.00 target price for the company in a research note on Wednesday, April 6th. Citigroup Inc. raised shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 27th. Bank of America Corp. reissued a “hold” rating and issued a $65.00 price objective on shares of ResMed in a research note on Sunday, July 10th. BMO Capital Markets reissued a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Finally, Canaccord Genuity reissued a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Three analysts have rated the stock with a sell rating, six have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of C$59.69.

The company has a market capitalization of $9.25 billion and a P/E ratio of 27.00. The firm’s 50 day moving average price is $62.07 and its 200 day moving average price is $58.49.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Tuesday, April 26th. The company reported $0.68 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.69 by $0.01. The business had revenue of $453.90 million for the quarter, compared to the consensus estimate of $455.32 million. During the same period in the previous year, the company earned $0.65 EPS. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. Equities research analysts forecast that ResMed Inc. will post $2.66 earnings per share for the current fiscal year.

In other news, insider James Hollingshead sold 4,458 shares of the stock in a transaction dated Wednesday, June 15th. The shares were sold at an average price of C$59.40, for a total value of C$264,805.20. Following the completion of the sale, the insider now directly owns 43,422 shares in the company, valued at C$2,579,266.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider David Pendarvis sold 6,000 shares of the stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of C$56.02, for a total transaction of C$336,120.00. Following the completion of the sale, the insider now owns 80,287 shares of the company’s stock, valued at C$4,497,677.74. The disclosure for this sale can be found here.

Other large investors have modified their holdings of the company. Airain ltd acquired a new stake in shares of ResMed during the fourth quarter worth approximately $2,500,000. KBC Group NV boosted its stake in shares of ResMed by 36.7% in the fourth quarter. KBC Group NV now owns 43,904 shares of the company’s stock worth $2,357,000 after buying an additional 11,795 shares during the period. TrimTabs Asset Management LLC acquired a new stake in shares of ResMed during the fourth quarter worth approximately $2,189,000. Dimensional Fund Advisors LP boosted its stake in shares of ResMed by 5.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 314,665 shares of the company’s stock worth $16,896,000 after buying an additional 15,783 shares during the period. Finally, Advisors Asset Management Inc. boosted its stake in shares of ResMed by 370.0% in the fourth quarter. Advisors Asset Management Inc. now owns 20,878 shares of the company’s stock worth $1,121,000 after buying an additional 16,436 shares during the period.

ResMed Inc is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.